ORIGINAL RESEARCH

Left Atrial Remodeling and Stroke in Patients With Sinus Rhythm and Normal Ejection Fraction: ARIC-NCS

Francesco Bianco (b), MD, PhD; Raffaele De Caterina (b), MD, PhD; Alvin Chandra (b), MD; Iolanda Aquila, MD, PhD; Brian Claggett (b), PhD; Michelle C. Johansen (b), MD; Alexandra Gonçalves, MD, MMSc; Faye L. Norby (b), MS, MPH; Rebecca Cogswell, MD; Elsayed Z. Soliman (b), MD, MSc, MS; Rebecca Gottesman (b), MD, PhD; Thomas Mosley (b), PhD; Alvaro Alonso (b), MD, PhD; Amil Shah (b), MD, MPH; Scott D. Solomon (b), MD; Lin Yee Chen (b), MD, MS

BACKGROUND: Age-related left atrial (LA) structural and functional abnormalities may be related to subclinical cerebral infarcts (SCIs) and stroke. We evaluated the association of 3-dimensional echocardiographic LA contractility parameters with SCIs and stroke across the spectrum of tertiles of age increment in elderly patients with sinus rhythm, normal ejection fraction, and no history of atrial fibrillation.

METHODS AND RESULTS: We enrolled 407 participants (mean age, 76±8 years; 40% men) from ARIC-NCS (Atherosclerosis Risk in Communities Neurocognitive Study) undergoing a brain magnetic resonance imaging and 3-dimensional echocardiographic examinations in 2011 to 2013. The sample was analyzed among age tertiles and subgroups: no cerebral magnetic resonance imaging–detectable infarcts (n=315), magnetic resonance imaging–diagnosed SCIs (n=58), and clinically diagnosed stroke (n=34). The frequency of SCIs significantly increased over age tertiles (*P* trend 0.023). LA global longitudinal strain—a 3-dimensional echocardiographic index of LA reservoir function—and E/e' divided by LA global longitudinal strain—an index of LA stiffness—worsened across age tertiles (*P* trend 0.014 and 0.001, respectively), and only in the categories of SCIs (*P* trend <0.001 and 0.045, respectively) and stroke (*P* trend 0.001 and 0.011, respectively). LA global longitudinal strain was negatively associated with increased odds of SCIs (*P*=0.036, *P*=0.008, and *P*=0.001, respectively) and strokes (*P*=0.043, *P*=0.010, respectively). E/e' divided by LA global longitudinal strain was positively associated with the presence of SCIs (*P*=0.037, *P*=0.007, and *P*=0.001, respectively) and strokes (*P*=0.040) and not for clinical stroke.

CONCLUSIONS: In a large cohort study of elderly patients, among participants with sinus rhythm, normal ejection fraction, and no history of atrial fibrillation, measures of worse age-related LA reservoir function and stiffness are associated with higher odds of SCIs and stroke.

Key Words: 3-dimensional echocardiography = left atrial function = left atrial stiffness = left atrial strain = subclinical cerebral infarctions

Stroke is a well-recognized health problem that affects ≈795 000 people every year and accounts for 1 in 20 deaths in the United States.¹ Changes

in left atrial (LA) structure and function are wellrecognized factors that contribute to the development of atrial fibrillation (AF), heart failure (HF),² and ischemic

Correspondence to: Scott D. Solomon, MD, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. Email: ssolomon@rics.bwh.harvard.eduand Raffaele De Caterina, MD, PhD, Cardiology Division, Pisa University Hospital, Via Paradisa, 2, 56124 Pisa, Italy. Email: raffaele.decaterina@unipi.it

Supplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.121.024292

For Sources of Funding and Disclosures, see page 11.

^{© 2022} The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

JAHA is available at: www.ahajournals.org/journal/jaha

CLINICAL PERSPECTIVE

What Is New?

- The pathophysiology of cardioembolic stroke classically implies left atrial (LA) clot formation, and embolization, only in the presence of atrial fibrillation or reduced left ventricular ejection fraction.
- We demonstrated that in elderly patients, LA stiffness and reservoir function impairment is likely sufficient in LA clot formation and cerebral embolization.

What Are the Clinical Implications?

- These findings suggest the brain is an organ at risk for subclinical cerebral infarcts caused by LA senescence, raising the hypothesis that minor forms of LA dysfunction, early detectable by 3-dimensional echocardiography, may cause LA blood stasis.
- As a clinical prospective, LA global longitudinal strain routine assessment could serve as an early marker of atrial senescence and guide anticoagulation therapy, even in the absence of atrial fibrillation.

Nonstandard Abbreviations and Acronyms					
3DE	3-dimensional echocardiography				
ARIC	Atherosclerosis Risk in Communities				
GLS	global longitudinal strain				
LAV	left atrial volume				
SCI	subclinical cerebral infarct				

stroke.^{3,4} Only 0.2% to 0.4% of cerebral thromboembolic events are clinically apparent; the majority are asymptomatic, and thus defined as subclinical cerebral infarcts (SCIs).⁵ The presence of SCIs is associated with more severe stroke later in life.^{5,6}

Approximately 25% of ischemic strokes are caused by cardioembolism, with the most common mechanism being AF.^{1,7} Blood stasis in the left atrium from AF increases the risk of thromboembolism secondary to clot formation.^{3,4} Changes in LA structure and function (conduit, reservoir, and pump) can be related to several conditions, including amyloidosis and other cardiomyopathies,^{8,9} but LA remodeling may also occur as a result of aging and in the presence of age-related comorbidities, such as increased vascular stiffness, longstanding hypertension, and HF with preserved ejection fraction (EF).² Speckle tracking echocardiography has recently emerged as a quantitative technique to estimate myocardial function by the analysis of the motion of speckles in 2-dimensional ultrasound images. This technique allows a non-Doppler angle-independent objective analysis of myocardial deformation, with the possibility to quantify the thickening, shortening, and rotation dynamics of the heart muscle.¹⁰ A specific application of speckle tracking echocardiography, the LA global longitudinal strain (GLS), measures LA reservoir function and LA stiffness—the ratio of mitral inflow E/e' to LA (GLS) and LA EF—seems to lessen with age.^{11,12}

Therefore, we hypothesized that age-related alterations in LA structure and function (reservoir and stiffness, in particular) in individuals with sinus rhythm and normal EF would be associated with SCIs and clinical stroke independently from the presence and history of AF. So, we aimed at assessing whether LA remodeling and impairment in contractility, detected by 3-dimensional echocardiography (3DE) and observed across the spectrum of tertiles of age increments, are associated with SCIs and clinical stroke among participants with normal EF, in sinus rhythm, and with no history of AF in the large cohort of ARIC-NCS (Atherosclerosis Risk in Communities Neurocognitive Study).

METHODS

The authors declare that all supporting data are available within the article and its online supplementary files.

Study Population and Design

From 1987 to 1989, the ARIC (Atherosclerosis Risk in Communities) study enrolled and examined 15 792 men and women aged 45 to 64 years recruited from 4 communities in the United States (Forsyth County, NC; Jackson, MS; Minneapolis suburbs, MN; and Washington County, MD). Participants were mostly of White race in the Minneapolis and Washington County sites, of White and Black race in Forsyth County, and only of Black race in Jackson. After their baseline examination, participants underwent follow-up visits in 1990 to 1992, 1993 to 1995, 1996 to 1998, 2011 to 2013, 2016 to 2017 (visits 2–6), and 2018 to 2019 (visit 7). Participants have since then been followed up via annual phone calls (semiannual since 2012).¹³

A detailed rationale of the study design and procedures has been previously published.¹⁴ Of 6538 participants seen at visit 5 (2011–2013), 1906 participants underwent brain magnetic resonance imaging (MRI) examination. Of these, 1184 underwent a 3DE examination and were considered for this study. Patients were randomly selected for the examinations mentioned above. Of these 1184 participants, we included patients in sinus rhythm, without history of AF or atrial flutter, and with normal EF (\geq 50%) on visit 5 transthoracic echocardiogram, excluding participants with insufficient 3DE image quality (n=336) (Table S1). We also excluded 777 participants: 207 presenting with moderate or severe valvular regurgitation and 170 with valvular stenoses. Previous surgery for valve replacement was also considered an exclusion criterion (n=64).

The history of AF or atrial flutter was ascertained from hospitalization discharge records during follow-up (from visit 3–5), or by an ECG performed during any ARIC study visit, including visit 5.¹⁵ Ultimately, a total of 407 participants constituted the sample for the present analysis. A flow chart of the patient selection in the study is presented in Figure S1.

The institutional review board of each center approved the ARIC study protocol and informed consent was obtained from every participant.

Variable Definitions SCIs and Stroke

At each field center, brain MRI was performed on 3-Tesla Siemens scanners (various models) using a common, and also recommended,¹⁶ set of sequences that included 3-dimensional volumetric magnetizationprepared gradient echo and fluid-attenuated inversion recovery (diffusion-weighted imaging, fluid-attenuated inversion recovery MRI, and T2-weighted imaging). SCIs were defined as focal, nonmass, and nonlacunar lesions of \geq 3 mm, bright on T2-weighted sequences and dark on T1-weighted images.¹⁴ The infarcts were identified, measured, and counted by a trained imaging technician and confirmed by radiologists as previously described.¹⁷

Stroke was adjudicated by a panel of physicians based on diagnosis of stroke from hospital records and death certificates using validated criteria from the National Survey of Stroke by the National Institute of Neurological Disorders and Stroke classification and supported by a computerized algorithm.¹⁸ In this study, we evaluated ischemic stroke.

Echocardiography

Methods for conventional and 3DE acquisition and quantitative analysis, including reproducibility metrics, have been previously reported.^{19,20} All echocardiograms were performed using dedicated Philips iE33 Ultrasound systems with Vision 2011; each examination was performed using an X3-1 iE33 transducer (Philips Medical Systems). Images were transferred to the Echocardiography Reading Center at the Brigham and Women's Hospital, Boston, MA, where echocardiographic measures were performed and over-read, blinded to the clinical characteristics of participants. Conventional echocardiographic measures including left ventricular (LV) linear dimensions and volumes, LV EF, LA parasternal linear dimensions, and right ventricular functional parameters were measured according to the recommendations from the American Society of Echocardiography guidelines.²¹ Deformation analysis, including 3-dimensional LA strain measurements, were measured using semiautomated quantification software 4-dimensional left ventricle analyses 2.0 (TomTec Imaging Systems), as previously described.²

Three-Dimensional LA Analysis

The 3DE acquisition protocol and analysis have been previously described in detail.² In the 3-dimensional real-time data sets, the TomTec software automatically selects the 2-, 3-, and 4-chamber views, from 4 consecutive cardiac cycles, and then detects the blood-tissue interface with an offline contourtracking algorithm. Where required, a manual adjustment was also systematically applied. The LA appendage and the pulmonary veins orifices were excluded from the tracing. LA endocardial surface was reconstructed throughout the cardiac cycle, resulting in a dynamic cast of LA cavity. For each consecutive frame, the voxel count inside the 3-dimensional surface was used to measure LA volume (LAV), resulting in a smooth interpolated LAV time curve allowing detection of the maximal (LAV max) and minimal (LAV min) LAVs. In this way, LA EF and stroke volume, two measures of LA contractile function, were assessed.

LA emptying fraction, an estimate of LA reservoir function, was calculated as ([LAV max–LAV min]/LAV max×100), while LA conduit volume was assessed by the following formula: LV stroke volume–(LAV max–LAV min).⁴ In addition, 3DE LA speckle-tracking analysis was automatically performed throughout the cardiac cycle, using the P wave as the reference point, with measurements of LA GLS as a surrogate of LA reservoir function. The ratio of mitral inflow E/e' to LA GLS and LA EF was used to estimate LA stiffness.¹²

Image quality was judged based on stitch/artifacts ratio and quality resolution of LA segments throughout the whole cardiac cycle. In the presence of stitching artifacts or dropout of >2 LA segments, the image was excluded from analysis. 3DE LAV measurements were repeated in a randomly selected group of 40 participants by 2 additional investigators at least 1 month later, both blinded to the results of all previous measurements.²

Other Variables

The ARIC staff obtained baseline demographic data, medication use, and medical history from the participants during visit 5.²² We included in our analysis age, sex, race, body mass index, body surface area (according to the Du Bois formula: body surface area m²=0.007184×(height (cm) 0.725×weight (kg) 0.425)), CHA₂DS₂-VASc score, cigarette smoking status, presence of coronary heart disease, HF with preserved EF, diabetes, use of antihypertensive, antiplatelet and anticoagulant drugs, systolic and diastolic blood pressure, and blood biomarkers.

The definition of HF with preserved EF was based on a prior history of hospitalization for HF or a selfreported physician diagnosis of HF or HF medication use at visit 5 and an LV EF \geq 50% by visit 5 echocardiogram.⁹ The use of HF medications was obtained by asking cohort patients whether they had taken HF medications in the 2 weeks before the study visit.⁹

Myocardial infarction was defined based on the presence of adjudicated events according to previously published criteria.²³ Body mass index was defined as weight/(height)² (in kilograms per squared meters). Diabetes was defined as a fasting (minimum of 8 hours) glucose level ≥126 mg/dL, nonfasting glucose ≥200 mg/dL, self-reported use of oral hypoglycemic agents or insulin, or self-reported physician diagnosis of diabetes. Smoking status was self-reported. Participants were classified as current smokers and noncurrent smokers.²²

Hypertension was defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or medication being taken for high blood pressure during the past 2 weeks before the visit. Total cholesterol, high-density lipoprotein cholesterol, and triglyceride levels were measured in a centralized laboratory.²⁴ NT-pro BNP (N-terminal pro-B-type natriuretic peptide) was measured using electrochemiluminescent immunoassay (Roche Diagnostics) with a lower detection limit of 5 pg/mL.^{2,25} Concentrations of high-sensitivity cardiac troponin were measured with a high-sensitivity sandwich immunoassay from stored plasma samples (-80°C) drawn at visits 2, 4, and 5. The samples were analyzed at the University of Minnesota (Minneapolis) and Baylor College of Medicine (Houston, TX) using a high-sensitivity assay (Elecsys Troponin T; Roche Diagnostics) on an automated analyzer (Cobas e411; Roche Diagnostics).²⁵ The limit of detection for high-sensitivity cardiac troponin T level was 5 ng/L, and the limit of blank was 3 ng/L.²⁶ Estimated glomerular filtration rate was calculated based on circulating creatinine and cystatin C levels using the Chronic Kidney Disease Epidemiology Collaboration formula.²⁷

Statistical Analysis

We analyzed the sample across the spectrum of tertiles of age increments (age tertile $1=68\pm2$ years, age tertile $2=76\pm2$ years, and age tertile $3=83\pm3$ years), and then categorized participants into 3 groups: group 1 (n=315) consisted of those with no cerebral infarcts on brain MRI scans and without previous history of stroke; group 2 (n=58) consisted of those without clinical history of stroke but with MRI evidence of SCI; and group 3 (n=34) consisted of participants with both a history of clinical stroke as well as MRI evidence of cerebral infarcts.

Categorical values are expressed as absolute number and percentage, while continuous variables are expressed as mean±SD or median and interguartile intervals (quartile 1-quartile 3), as appropriate. Mean values of echocardiographic characteristics and corresponding SEs are presented according to tertiles of age increment and cerebral infarcts, after adjusting for sex, race, body mass index, body surface area, comorbidities, and medications. Comorbidities included hypertension, diabetes, previous myocardial infarction, and renal function. Medications included the use of anticoagulants, antiplatelet agents, Bblockers, and loop diuretics. Statistical comparisons across age tertiles and types of cerebral infarcts (no cerebral infarcts, SCIs, and stroke--all of the possible phenotypes of ischemic cerebral infarcts) were made with linear regression and chi-square tests for trend.

We used a stepwise ordered multivariable logistic regression (forward adding all of the variables with a P<0.05) to estimate the odds ratios (ORs) and 95% CIs of both clinical and echocardiographic variables for 2 outcomes: (1) MRI-determined SCIs, and (2) clinically diagnosed stroke. Covariates were selected based on their potential relationship with SCIs and strokes, stratified for age tertiles. All of the potentially relevant covariates^{2,5,8,11,12} that showed statistically significant associations (P<0.05) on the trend test were included in the models: sex, race, body surface area, body mass index, blood pressure, heart rate, hypertension, previous myocardial infarction, diabetes, renal function, NT-proBNP, troponin levels, use of anticoagulants and antiplatelet agents, CHA2DS2-VASc score, and relevant echocardiographic parameters (LV indexed volumes and linear measures, EF, LV mass index, diastolic function parameters, and all of the LA structure and function parameters). The interaction term for outcomes (SCIs and stroke) between age tertiles and predictors were then assessed through a logistic regression model.

All statistical analyses were performed with Stata version 14.1 (StataCorp LLC). *P* values <0.05 were considered statistically significant.

RESULTS

Participant Characteristics

The final analytic sample consisted of 407 ARIC participants (mean age, 76±8 years; 40% men). More than half were women (60%) and 21% were of Black race. Hypertension was present in more than two thirds of the sample and diabetes in approximately one third, while 63% of patients were current smokers. A total of 26 (6%) patients had HF with preserved EF; its frequency slightly increased across the age tertiles but not to a statistically significant level. Aspirin was the antiplatelet agent in our sample, with 69% of patients being current users; only 2% were taking anticoagulants and almost half were on statin treatment.

Demographic and clinical characteristics stratified by age tertiles are presented in Table 1. Age distribution among tertiles was age tertile 1=68±2 years (n=136), age tertile 2=76±2 years (n=136), and age tertile 3=83±3 years (n=135). The frequency of SCIs significantly increased over age tertiles (*P* trend 0.023), while no increase was found with respect to clinical stroke (Figure S2). As expected, and even if in sinus rhythm, patients of older ages had a higher CHA₂DS₂-VASc score (*P* trend <0.001), higher blood pressure values (*P* trend<0.001), and reduced estimated glomerular filtration rate (*P* trend <0.001). Significant trend differences were also found with respect to troponin and NT-proBNP levels (both *P* trend=0.001) (Table 1).

Echocardiographic Characteristics

After adjustments, LV end-systolic and end-diastolic diameters and end-diastolic volume diminished in those of older ages (*P* trend=0.005, 0.002, and 0.012, respectively), even when volumes were indexed (*P* trend=0.01 and 0.004) (Table 2). Similarly, the interventricular septum thickness and LV relative wall thickness were greater in age tertile 3 than age tertiles 2 and 1 (*P* trend 0.024 and 0.004, respectively). The E/e' ratio increased through the age tertiles, while there was no statistically significant trend difference in LV EF according to age increment.

Adjusted mean 2-dimensional echocardiographic and 3DE characteristics according to age tertiles and cerebral infarcts subgroups phenotypes (SCI and stroke) are presented in Table 3. In the SCI group, the E/e' ratio significantly increased according to tertiles of age increment (*P* trend *P*<0.001), while in the stroke group, along with E/e' ratio growth, we also observed an LV relative wall thickness increase from age tertile 1 to 3 (*P*=0.015 and *P*=0.042, respectively). No differences were found regarding LV volumes and linear dimensions, LV EF, and diastolic function (E/A and E/e' ratio) in the no cerebral infarcts subgroups (Table S2).

LA Structural and Functional Characteristics

LA structural and functional parameters are presented in Tables 2 and 3; all values are shown after adjustments. While still within the normal range (\leq 34 mL/ m²),²¹ LA indexed volume significantly increased across age tertiles in the SCIs group (*P* trend=0.003). This was accompanied by a decrease in LA EF and emptying fraction (*P* trend=0.008 and 0.009, respectively). No differences were found regarding the abovementioned 3DE parameters in the clinical stroke group.

LA GLS—a 3DE index of LA reservoir function decreased across age tertiles (*P* trend 0.014) and worsened across both SCIs and stroke groups (*P* trend <0.001 and 0.045, respectively) (Figure), while E/e' divided by LA GLS—an index of LA stiffness increased among age tertiles (*P* trend 0.001) and was progressively impaired over SCIs and stroke groups (*P* trend=0.001 and 0.011, respectively) (Tables 2 and 3). No differences were found regarding the abovementioned 3DE parameters in the no cerebral infarcts group (Table S1).

Outcome Analysis

The results of multivariable analysis are shown in Table 4. NT-proBNP (per 1 ng/L) and CHA_2DS_2 -VASc score (per 1 point) were both significantly associated with increased odds of SCIs, while the latter variables plus high-sensitivity troponin T (per 1 ng/mL) with stroke.

LA GLS was negatively associated with increased odds of SCIs (P=0.036, P=0.008, and P=0.001, respectively) and strokes (P=0.043, P=0.015, and P=0.001, respectively) among age tertiles, with a significant interaction between age tertiles (interaction P=0.043 and P=0.010, respectively). E/e' divided by LA GLS was positively associated with the presence of SCIs (P=0.037, P=0.007, and P=0.001, respectively) and strokes (P=0.045, P=0.007, and P=0.003, respectively) over age tertiles, with a significant interaction only for SCIs (interaction P=0.040) and not for clinical stroke.

DISCUSSION

In the present analysis of the ARIC-NCS, among elderly participants who were in sinus rhythm, with normal EF (≥50%) and no history of AF, we observed an increased frequency of MRI-diagnosed SCIs across tertiles of age increment. After adjustments for potential confounders, we also observed that changes in atrial reservoir function and stiffness significantly worsened across the spectrum of cerebral infarcts phenotypes, from SCIs to stroke. In addition, these echocardiographic

Table 1. Clinical Characteristics of Study Participants According to Age Tertiles: the ARIC-NCS, 2011 to 2013

	Total	Age tertile 1	Age tertile 2	Age tertile 3	
General characteristics	N=407	n=136	n=136	n=135	P for trend
Age, y	76±8	68±2	76±2	83±3	0.001*
SCls, n (%)	58 (15)	14 (12)	17 (13)	27 (22)	0.023*
Stroke, n (%)	34 (10)	15 (12)	6 (5)	13 (12)	0.89
White race, n (%)	323 (79)	99 (73)	110 (81)	114 (84)	0.018*
Men, n (%)	165 (40)	56 (41)	56 (41)	53 (39)	0.75
Heart rate, beats per min	61±10	62±9	60±11	60±10	0.11
Systolic blood pressure, mm Hg	133±19	128±19	135±18	136±18	0.001*
Diastolic blood pressure, mm Hg	67±10.4	68±10	68±10	64±10	0.001*
CHA ₂ DS ₂ -VASc score	4 (3-4)	3 (3–4)	4 (3-4)	6 (5–7)	0.001*
Height, cm	165±9	166±9	165±9	163±8	0.008*
Weight, kg	75±15	77±16	75±15	71±14	0.001*
BMI, kg/m²	27±5	28±5	27±5	26±5	0.020*
Previous myocardial infarction, n (%)	21 (5)	7 (5)	7 (5)	7 (5)	0.94
HF with preserved EF, n (%)	26 (6)	7 (5)	8 (6)	11 (8)	0.31
Diabetes, n (%)	152 (37)	54 (40)	51 (37)	47 (35)	0.41
Hypertension, n (%)	334 (82)	103 (76)	111 (82)	120 (90)	0.005*
Current and former smoker, n (%)	255 (63)	83 (61)	91 (67)	81 (60)	0.86
Chronic kidney disease, n (%)	26 (6.3)	7 (5)	8 (6)	11 (8)	0.31
Blood samples			·		
eGFR	75±19	80.7±17.2	72.9±20.3	72±20	0.001*
Total cholesterol, mg/dL	180±41	183.8±42.4	182.0±42.7	175±38	0.08
LDL, mg/dL	103±33	106.3±34.0	105.4±33.7	98±33	0.06
HDL, mg/dL	52±14	52.4±13.8	52.5±15.1	52±13	0.88
Triglycerides, mg/dL	124±58	129.5±64.7	120.9±55.0	123±54	0.33
Glucose, mg/dL	113±33	116.3±41.2	112.9±30.4	111±26	0.16
Creatinine, mg/dL	1±0.4	0.9±0.2	1±0.5	1±0.3	0.07
hs-CRP, mg/dL	1.6 (0.8–3.5)	1.7 (0.7–3.2)	1.5 (0.8–3.8)	1.8 (1–3.8)	0.27
High-sensitivity troponin T, ng/mL	1 (0.7–1.5)	0.8 (0.5–1.3)	1 (0.7–1.4)	1.2 (0.8–1.7)	0.001*
NT-proBNP, ng/L	131 (70–233)	79 (45–135)	132 (69–240)	192 (121–344)	0.001*
Medications					
Statins, n (%)	193 (48)	66 (48)	63 (47)	64 (48)	0.90
Anticoagulants, n (%)	9 (2)	4 (3)	3 (2)	2 (1)	0.42
Aspirin, n (%)	279 (69)	88 (65)	89 (66)	102 (76)	0.043*
β-blockers, n (%)	110 (27)	41 (30)	32 (24)	37 (28)	0.64
Antiangiotensin II, n (%)	42 (10)	8 (6)	11 (8)	23 (17)	0.002*
ACEI, n (%)	88 (22)	23 (17)	36 (27)	29 (22)	0.34
Loop diuretics, n (%)	36 (9)	15 (11)	13 (9)	8 (6)	0.15
<u>`</u>	· · · ·				

Data are described as mean (±SD) or median (quartile 1–quartile 3) for quantitative variables, and counts (proportions) for categorical variables. ACEI indicates angiotensin-converting enzyme inhibitor; ARIC-NCS, Atherosclerosis Risk in Communities Neurocognitive Study; BMI, body mass index; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HF, heart failure; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; LV, left ventricular; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and SCIs, subclinical cerebral infarcts.

 $\ensuremath{\,^{\ast}\text{Denotes}}$ statistically significant differences across groups for the selected variable.

indices were significantly associated with increased odds of SCIs and stroke, demonstrating a significant interaction with age for SCIs.

Traditionally, the pathophysiology of cardioembolic stroke implies the presence of AF²⁸ and a structurally abnormal or dilated atrium producing blood stasis and thrombus

formation, in accordance with the Virchow triad.⁷ In this regard, previous studies have demonstrated that abnormal P-wave axis and prolonged P-wave duration (ECG surrogates of LA abnormality) are associated with an increased risk of AF²⁹ and cerebrovascular events.²⁵ In addition, Cogswell et al⁸ recently reported an increased prevalence

Table 2. Adjusted Mean 2DE and 3DE Characteristics According to Age Tertiles: ARIC-NCS, 2011 to 2013

N=407 n=136 n=136 n=136 ZDE Z		Total	Age tertile 1	Age tertile 2	Age tertile 3	P for trend		
DDE LV dend-diastolc diameter, cm 4.3a.0.50 4.42 (0.04) 4.32 (0.04) 4.24 (0.04) 0.009* LV end-systolic diameter, cm 2.55 (0.04) 2.47 (0.04) 2.37 (0.04) 0.002* Interventricular septum thickness, cm 1.14.0.20 1.04 (0.01) 1.05 (0.01) 0.05 (0.01) 0.02* Posterior wall thickness, cm 0.39.0.10 0.38 (0.01) 0.39 (0.01) 0.02* 0.06* LV end-diastolic volume, ml. 274.11 28 (0.84) 27 (0.77) 26 (0.82) 0.06* LV end-diastolic volume indexed, mL/m ² 454.11 47 (0.91) 45 (0.83) 44 (0.89) 0.01* LV and-systolic volume indexed, mL/m ² 155.00 15 (0.46) 14 (0.42) 14 (0.43) 0.08 LV and-systolic volume indexed, mL/m ² 454.11 47 (0.31) 67 (0.58) 67 (0.58) 0.71 LV and systolic volume indexed, mL/m ² 106.19 17 (0.58) 67 (0.58) 0.74 LV mass, index, gm ² 0.54.0 0.54 (0.01) 0.44 (0.01) 0.44 (0.01) 0.004* LV relative wall thickn		N=407	n=136	n=136	n=135	-		
LV end-diastolic diameter, cm 4.3±0.50 4.42 (0.04) 4.32 (0.04) 4.24 (0.04) 0.005' LV end-systolic diameter, cm 2.55 (0.04) 2.47 (0.04) 2.37 (0.04) 0.002' Interventricular septum thickness, cm 1.1±0.20 1.04 (0.01) 1.09 (0.01) 0.92 (0.01) 0.05' LV end-systolic volume, mL 89.3±23 86 (16.4) 82 (1.50) 80 (1.80) 0.01' LV end-systolic volume, mL 27.11 28 (0.84) 27 (0.7) 26 (0.82) 0.06' LV end-systolic volume indexed, mL/m ² 45±11 47 (0.91) 45 (0.83) 44 (0.89) 0.011' LV end-systolic volume indexed, mL/m ² 67±50 67 (0.51) 67 (0.55) 67 (0.51) 67 (0.51) 67 (0.51) 67 (0.51) 67 (0.51) 67 (0.51) 67 (0.51) 67 (0.51) 67 (0.51) 67 (1.50) 67 (1.50) 67 (1.50) 67 (1.50) 67 (1.50) 67 (1.50) 67 (1.50) 67 (1.50) 67 (1.50) 67 (1.50) 67 (1.50) 67 (1.50) 67 (1.50) 67 (1.50) 67 (1.50) 67 (1.50) 67 (1.50) 67 (1.50) <td colspan="8">2DE</td>	2DE							
L V end-diastolic diameter, cm4.3±0.504.42 (0.04)4.32 (0.04)4.24 (0.04)0.006"L V end-systolic diameter, cm2.55 (0.04)2.57 (0.04)0.06"<	LV dimensions and function							
L V and-systolic diameter, cm2.55 (0.04)2.47 (0.04)2.37 (0.04)0.002*Interventricular segmun thickness, cm0.940 (000.88 (0.01)0.90 (00)0.26 (0.01)0.26 (0.01)Posterior valid hickness, cm0.940 (000.88 (0.01)0.82 (0.01)0.	LV end-diastolic diameter, cm	4.3±0.50	4.42 (0.04)	4.32 (0.04)	4.24 (0.04)	0.005*		
Interventrioular septum thickness, cm 11±0.20 1.04 (0.01) 1.09 (0.01) 1.10 (0.01) 0.024' Posterior wall thickness, cm 0.94.010 0.88 (0.01) 0.96 (0.01) 0.92 (0.01) 0.05 LV end-diastolic volume, mL 234.23 86 (1.84) 27 (10.77) 26 (0.82) 0.06 LV end-systolic volume indexed, mL/m ² 452.11 47 (0.91) 45 (0.83) 44 (0.89) 0.011' LV end-systolic volume indexed, mL/m ² 156.04 14 (0.42) 14 (0.42) 0.93 LV res, g 1464.43 144 (3.30) 15 (3.0) 144 (3.20) 0.93 LV mass index, g/m ² 80 x19 79 (1.80) 83 (1.60) 78 (1.80) 0.04' LV diative wall thickness, cm 0.94 0.30 0.40 (0.01) 0.44 (0.10) 0.44 (0.20) 0.33 LV diative wall thickness, cm 0.94 0.30 0.96 (0.5) 0.87 (0.30) 0.90 (0.5) 0.20 LV diative wall thickness, cm 0.94 0.30 0.90 (0.3) 0.20 (0.3) 0.20 0.33 LV diative wall thickness, cm 0.94 0.30 0.60 (0.3)	LV end-systolic diameter, cm	2.5±0.40	2.55 (0.04)	2.47 (0.04)	2.37 (0.04)	0.002*		
Posterior wail thickness, cm0.9±0.010.88 (0.01)0.95 (0.01)0.92 (0.01)0.05I.V end-diastolic volume, mL87.21086 (1.64)82 (1.50)80 (1.60)0.01*I.V end-diastolic volume, mL77.1182 (0.84)27 (0.77)82 (0.82)0.06I.V end-diastolic volume indexed, mL/m²45.15147 (0.91)45 (0.83)44 (0.49)0.01*I.V end-systolic volume indexed, mL/m²675.0567 (0.51)67 (0.56)67 (0.58)0.71I.V ras, g146-43144 (3.00)63 (1.60)76 (1.60)0.740.04*I.V rass, g146-43144 (3.01)83 (1.60)76 (1.60)0.760.04*I.V rass g0.43±0.080.40 (0.01)0.44 (0.01)0.04*0.04*I.V rass g0.43±0.080.96 (0.03)0.87 (0.03)0.90 (0.03)0.20I.V rass g0.94±0.020.940.04*0.04*0.04*I.V rats g0.94±0.020.96 (0.03)0.87 (0.03)0.90 (0.03)0.20I.V rats g0.94±0.0212±4.0410.04.0111.0360.200.04*I.V rats g12±4.02100.0411.03612.03.010.04*I.V rats g0.94±0.0212±4.0210.04.0110.030.04*I.V rats g0.94±0.0212±4.0210.04.0110.030.04*I.V rats g0.94±0.0212±4.0210.04.0110.030.04*I.V rats g0.94±0.0212±4.0210.04.0110.030.04*I.	Interventricular septum thickness, cm	1.1±0.20	1.04 (0.01)	1.09 (0.01)	1.10 (0.01)	0.024*		
LV end-diastolic volume, mL 83±23 86 (1.64) 82 (1.50) 80 (1.60) 0.012' LV end-systolic volume, mL 27 x11 28 (0.84) 27 (0.77) 26 (0.82) 0.061 LV end-systolic volume indexed, mL/m ² 45 ±11 47 (0.91) 45 (0.83) 44 (0.89) 0.011' LV end-systolic volume indexed, mL/m ² 15 ±50 15 (0.64) 14 (0.42) 14 (0.43) 0.06 LV F s/k 67 ±50 67 (0.51) 67 (0.56) 67 (0.58) 0.71 LV mass, g 148±43 144 (3.30) 151 (30) 144 (0.32) 0.93 LV relative wall thickness, cm 0.43 n.08 0.40 (0.01) 0.44 (0.01) 0.004' LV elative wall thickness, cm 0.43 n.08 0.40 (0.01) 10.48 (0.01) 0.90 (0.03) 0.20 LV diastolic function E E 12 ±40 10 (0.40) 11 (0.36) 12 (0.39) 0.004' Deceleration time, mL 61 ±20 60 (1.60) 59 (1.50) 61 (1.60) 0.61 LA maximal volume, mL 61 ±20 50 (1.60) 50 (1.	Posterior wall thickness, cm	0.9±0.10	0.88 (0.01)	0.95 (0.01)	0.92 (0.01)	0.05		
LV end-systolic volume, mL 27±11 28 (0.84) 27 (0.77) 26 (0.82) 0.06 LV end-diastolic volume indexed, mL/m ² 45±11 47 (0.91) 45 (0.83) 44 (0.89) 0.011* LV end-diastolic volume indexed, mL/m ² 15±60 15 (0.46) 14 (0.42) 14 (0.45) 0.06 LV FE, % 67±50 67 (0.59) 67 (0.59) 67 (0.59) 0.71 LV mass index, g/m ² 80±19 79 (1.80) 151 (30) 144 (3.20) 0.33 LV relative wall thickness, cm 0.340.08 0.40 (0.01) 0.44 (0.01) 0.40 (0.01) 0.44 (0.01) 0.00* LV relative wall thickness, cm 0.340.08 0.40 (0.01) 0.44 (0.01) 0.40 (0.01) 0.40 (0.01) 0.44 (0.01) 0.00* LV relative wall thickness, cm 0.340.08 0.40 (0.01) 0.41 (0.01) 0.41 (0.01) 0.41 (0.01) 0.41 (0.01) 0.41 (0.01) 0.00* LV relative wall thickness, cm 0.340.08 0.56 (0.03) 0.57 (0.03) 0.90 (0.03) 0.02* LV relative wall thickness, cm 0.24±0 210 (0.7) <td>LV end-diastolic volume, mL</td> <td>83±23</td> <td>86 (1.64)</td> <td>82 (1.50)</td> <td>80 (1.60)</td> <td>0.012*</td>	LV end-diastolic volume, mL	83±23	86 (1.64)	82 (1.50)	80 (1.60)	0.012*		
LV end-diastolic volume indexed, mL/m ² 45 ±11 47 (0.91) 45 (0.83) 44 (0.89) 0.011* LV end-systolic volume indexed, mL/m ² 15 ±50 15 (0.46) 14 (0.42) 14 (0.45) 0.06 LV ress, g 67 (0.51) 67 (0.53) 67 (0.58) 0.71 0.33 LV mass, g 144±43 144 (0.30) 151 (30) 144 (3.20) 0.33 LV mass, g 144±43 144 (0.30) 0.44 (0.01) 0.44 (0.01) 0.004* LV relative wall thickness, cm 0.43±0.08 0.40 (0.01) 0.44 (0.01) 0.004* LV relative wall thickness, cm 0.43±0.08 0.96 (0.03) 0.87 (0.03) 0.90 (0.03) 0.20 E/A ratio 0.9±0.30 0.96 (0.03) 0.87 (0.03) 0.90 (0.03) 0.00* Deceleration time, ms 216±46 210 (4.70) 220 (4.30) 222 (4.60) 0.07* SUP L/Ms 61±20 60 (1.60) 59 (1.50) 61 (1.60) 0.61 LA maximal volume, mL 29±12 27 (1.00) 28 (0.91) 30 (0.99)	LV end-systolic volume, mL	27±11	28 (0.84)	27 (0.77)	26 (0.82)	0.06		
LV end-systolic volume indexed, mL/m² 15±50 15 (0.46) 14 (0.42) 14 (0.45) 0.06 LV FE, % 67±50 67 (0.51) 67 (0.56) 67 (0.58) 0.71 LV mass, g 146±43 144 (3.30) 151 (30) 144 (3.20) 0.93 LV mass, g/m² 80±19 79 (1.80) 83 (1.60) 78 (1.80) 0.76 LV relative wall thickness, cm 0.43±0.08 0.40 (0.01) 0.44 (0.01) 0.44 0.004* LV relative wall thickness, cm 0.43±0.08 0.96 (0.03) 0.87 (0.03) 0.90 (0.03) 0.20 LV relative wall thickness, cm 0.3±0.30 0.96 (0.03) 0.87 (0.03) 0.90 (0.03) 0.004* LV diastolic function 12 (4.01) 10 (0.40) 11 (0.36) 12 (0.59) 0.004* Deceleration time, ms 219±40 210 (4.70) 220 (4.30) 22 (4.60) 0.07* LA maximal volume, mL 61±20 60 (1.60) 59 (1.50) 61 (1.60) 0.61 LA maximal volume indexed, mL/m² 13±60 13 (0.54) 16 (0.59) 0.78 <td>LV end-diastolic volume indexed, mL/m²</td> <td>45±11</td> <td>47 (0.91)</td> <td>45 (0.83)</td> <td>44 (0.89)</td> <td>0.011*</td>	LV end-diastolic volume indexed, mL/m ²	45±11	47 (0.91)	45 (0.83)	44 (0.89)	0.011*		
LV EF, % 67 (0.51) 67 (0.58) 67 (0.58) 0.71 LV mass, g 146±43 144 (3.30) 151 (30) 144 (3.20) 0.93 LV mass index, g/m² 80:19 79 (1.80) 83 (1.60) 78 (1.80) 0.76 LV relative wall thickness, cm 0.43±0.08 0.40 (0.01) 0.44 (0.01) 0.044 LV diastolic function E/r ratio 0.9±0.30 0.96 (0.03) 0.87 (0.03) 0.90 (0.03) 0.20 E/e ratio, average 12±40 10 (0.40) 11 (0.36) 12 (0.39) 0.004* Deceleration time, ms 216±46 210 (4.70) 220 (4.30) 222 (4.60) 0.07 Stratis LANs 11 (0.40) 11 (0.36) 12 (0.39) 0.04* LANs 216±46 210 (4.70) 220 (4.30) 20 (0.97) 0.04* LANs 51±20 60 (1.60) 50 (1.50) 61 (1.60) 0.61 LA maximal volume, mL 19±20 27 (1.00) 28 (0.91) 30 (0.99) <t< td=""><td>LV end-systolic volume indexed, mL/m²</td><td>15±50</td><td>15 (0.46)</td><td>14 (0.42)</td><td>14 (0.45)</td><td>0.06</td></t<>	LV end-systolic volume indexed, mL/m ²	15±50	15 (0.46)	14 (0.42)	14 (0.45)	0.06		
LV mass, g 146±43 144 (3.30) 151 (30) 144 (3.20) 0.93 LV mass index, g/m ² 80±19 79 (1.80) 83 (1.60) 78 (1.80) 0.76 LV relative wall thickness, cm 0.43±0.08 0.40 (0.01) 0.44 (0.01) 0.44 (0.01) 0.044 (0.01) LV flastolic function 0.9±0.30 0.96 (0.03) 0.87 (0.03) 0.90 (0.03) 0.20 E/er ratio 0.9±0.30 0.96 (0.03) 0.87 (0.03) 0.90 (0.03) 0.20 Deceleration time, ms 216±46 210 (4.70) 220 (4.30) 222 (4.60) 0.07 Statistic function LA maximal volume, mL 61±20 60 (1.60) 59 (1.50) 61 (1.60) 0.61 LA minimum volume, mL 29±12 27 (1.00) 28 (0.91) 30 (0.99) 0.08 LA maximal volume indexed, mL/m ² 16±60 15 (0.50) 15 (0.50) 0.16 1.7 LA contractife function 15 (0.50) 15 (0.50) 0.16 1.7 LA stroke volume indexed, mL/m ² 18±60 <	LV EF, %	67±50	67 (0.51)	67 (0.56)	67 (0.58)	0.71		
LV mass index, g/m² 80±19 79 (1.80) 83 (1.60) 78 (1.80) 0.76 LV relative wall thickness, cm 0.43±0.08 0.40 (0.01) 0.44 (0.01) 0.004* LV diastolic function 0.90 (0.03) 0.90 (0.03) 0.20 E/A ratio 0.9±0.30 0.96 (0.03) 0.87 (0.03) 0.90 (0.03) 0.20 E/e ratio, average 12±40 10 (0.40) 11 (0.36) 12 (0.39) 0.004* Deceleration time, ms 216±46 210 (4.70) 220 (4.30) 222 (4.60) 0.07 3DE 59 (1.50) 61 (1.60) 0.61 LA maximal volume, mL 61±20 60 (1.60) 59 (1.50) 61 (1.60) 0.61 LA maximal volume, mL 29±12 27 (1.00) 28 (0.91) 30 (0.99) 0.08 LA contractife function 16±60 15 (0.50) 15 (0.54) 16 (0.59) 0.16 LA contractife function 16±60 18 (0.61) 17 (0.69) 0.48 LA stroke volume i	LV mass, g	146±43	144 (3.30)	151 (30)	144 (3.20)	0.93		
LV relative wall thickness, cm 0.43±0.08 0.40 (0.01) 0.44 (0.01) 0.44 (0.01) 0.004* LV diastolic function 0.96 (0.03) 0.87 (0.03) 0.90 (0.03) 0.20 E/A ratio 0.9±0.30 10 (0.40) 11 (0.36) 12 (0.39) 0.004* Deceleration time, ms 216±46 210 (4.70) 220 (4.30) 222 (4.60) 0.07 3DE 216±46 210 (4.70) 220 (4.30) 61 (1.60) 0.61 LA maximal volume, ms 61±20 80 (1.60) 59 (1.50) 61 (1.60) 0.61 LA maximal volume, mL 29±12 27 (1.00) 28 (0.91) 30 (0.99) 0.08 LA maximal volume indexed, mL/m ² 18±60 15 (0.50) 15 (0.54) 16 (0.59) 0.16 LA contractile function 18±60 18 (0.60) 17 (0.66) 17 (0.69) 0.48 LA emptying fraction, % 0.5±11 54 (1.01) 0.52 (0.01) 0.51 (0.01) 0.13 </td <td>LV mass index, g/m²</td> <td>80±19</td> <td>79 (1.80)</td> <td>83 (1.60)</td> <td>78 (1.80)</td> <td>0.76</td>	LV mass index, g/m ²	80±19	79 (1.80)	83 (1.60)	78 (1.80)	0.76		
LV diastolic function E/A ratio 0.9±0.30 0.96 (0.03) 0.87 (0.03) 0.90 (0.03) 0.20 E/a' ratio, average 12±40 10 (0.40) 11 (0.36) 12 (0.39) 0.004* Deceleration time, ms 216±46 210 (4.70) 220 (4.30) 222 (4.60) 0.07 SDE LAVs LA maximal volume, mL 61±20 60 (1.60) 59 (1.50) 61 (1.60) 0.61 LA maximal volume, mL 29±12 27 (1.00) 28 (0.91) 30 (0.99) 0.08 LA maximal volume indexed, mL/m ² 33±90 33 (0.90) 32 (0.87) 33 (0.88) 0.78 LA contractile function 16±60 15 (0.50) 15 (0.54) 16 (0.59) 0.16 LA contractile function 18±60 18 (0.60) 17 (0.69) 0.48 14 LA reservoir function 0.5±0.10 0.54 (0.01) 0.52 (0.01) 0.51 (0.01) 0.13 LA reservoir function 19±60 11 (0.60) 19 (0.66) 18 (0.68) 0.014' LA conduit functi	LV relative wall thickness, cm	0.43±0.08	0.40 (0.01)	0.44 (0.01)	0.44 (0.01)	0.004*		
E/A ratio 0.9 ± 0.30 $0.96(0.03)$ $0.87(0.03)$ $0.90(0.03)$ 0.20 E/e' ratio, average 12 ± 40 $10(0.40)$ $11(0.36)$ $12(0.39)$ 0.004^* Deceleration time, ms 216 ± 46 $210(4.70)$ $220(4.30)$ $222(4.60)$ 0.07 3DE LAVSLA maximal volume, mL 61 ± 20 $60(1.60)$ $59(1.50)$ $61(1.60)$ 0.61 LA maximal volume, mL 29 ± 12 $27(1.00)$ $28(0.91)$ $30(0.99)$ 0.08 LA maximal volume indexed, mL/m ² 33 ± 90 $33(0.90)$ $32(0.87)$ $33(0.88)$ 0.78 LA contractile functionLA track volume indexed, mL/m ² 18 ± 60 $18(0.60)$ $17(0.66)$ $17(0.69)$ 0.48 LA stroke volume indexed, mL/m ² 18 ± 60 $18(0.60)$ $17(0.66)$ $17(0.69)$ 0.48 LA stroke volume indexed, mL/m ² 18 ± 60 $18(0.60)$ $17(0.66)$ $17(0.69)$ 0.48 LA stroke volume indexed, mL/m ² 18 ± 60 $18(0.60)$ $17(0.66)$ $10.01)$ 0.13 LA stroke volume indexed, mL/m ² 18 ± 60 $18(0.60)$ $17(0.66)$ $18(0.68)$ 0.014^* LA stroke volume indexed, mL/m ² 18 ± 60 $18(0.60)$ $122(5.60)$ $118(6)$ 0.014^* LA stroke volume indexed, mL/m ² 32 ± 12 $33(1.20)$ $31(1.10)$ $31(1.20)$ 0.47 LA stroke volume, m	LV diastolic function	1	1	1	1			
É/e' ratio, average 12±40 10 (0.40) 11 (0.36) 12 (0.39) 0.004' Deceleration time, ms 216±46 210 (4.70) 220 (4.30) 222 (4.60) 0.07 3DE LAvis LA maximal volume, mL 61±20 60 (1.60) 59 (1.50) 61 (1.60) 0.61 LA maximal volume, mL 29±12 27 (1.00) 28 (0.91) 30 (0.99) 0.08 LA maximal volume indexed, mL/m2 33±90 33 (0.90) 32 (0.87) 33 (0.88) 0.78 LA contractile function 15 (0.50) 15 (0.54) 16 (0.59) 0.16 LA stroke volume indexed, mL/m2 18±60 18 (0.60) 17 (0.66) 17 (0.69) 0.48 LA EF, % 53±11 54 (1.20) 52 (1.01) 52 (1.01) 0.13 LA reservoir function 12±69 138 (0.60) 17 (0.66) 18 (0.61) 0.14' LA expansion index 12±619 138 (0.10) 0.52 (0.01) 0.51 (0.01) 0.33 LA conduit function 12±619 138 (6.10) 12	E/A ratio	0.9±0.30	0.96 (0.03)	0.87 (0.03)	0.90 (0.03)	0.20		
Deceleration time, ms 216±46 210 (4.70) 220 (4.30) 222 (4.60) 0.07 SDE LAVs LA 61±20 60 (1.60) 59 (1.50) 61 (1.60) 0.61 LA maximal volume, mL 61±20 27 (1.00) 28 (0.91) 30 (0.99) 0.08 LA maximal volume indexed, mL/m2 33±90 33 (0.90) 32 (0.87) 33 (0.88) 0.78 LA maximal volume indexed, mL/m2 16±60 15 (0.50) 15 (0.54) 16 (0.59) 0.16 LA contractile function U 16±60 18 (0.60) 17 (0.66) 17 (0.69) 0.48 LA storke volume indexed, mL/m2 18±60 18 (0.60) 17 (0.66) 15 (0.10) 0.13 LA emptying fraction, % 0.5±0.10 0.54 (0.01) 0.52 (0.01) 0.51 (0.01) 0.13 LA emptying fraction, % 0.5±0.10 0.54 (0.02) 0.52 (0.01) 0.51 (0.01) 0.13 LA esparsion index 19±60 21 (0.60) 19 (0.66) 18 (0.68) 0.014* LA expansion index 125±59	E/e' ratio, average	12±40	10 (0.40)	11 (0.36)	12 (0.39)	0.004*		
SDE LAVs 61±20 60 (1.60) 59 (1.50) 61 (1.60) 0.61 LA maximal volume, mL 29±12 27 (1.00) 28 (0.91) 30 (0.99) 0.08 LA maximal volume indexed, mL/m2 33±90 33 (0.90) 32 (0.87) 33 (0.88) 0.78 LA maximal volume indexed, mL/m2 16±60 15 (0.50) 15 (0.54) 16 (0.59) 0.16 LA minimum volume indexed, mL/m2 18±60 18 (0.60) 17 (0.66) 17 (0.69) 0.48 LA contractile function ULA stroke volume indexed, mL/m2 18±60 18 (0.60) 17 (0.66) 17 (0.69) 0.48 LA EF, % 53±11 54 (1.20) 52 (1.01) 52 (1.01) 0.13 LA emptying fraction, % 0.5±0.10 0.54 (0.01) 0.52 (0.01) 0.51 (0.01) 0.13 LA reservoir function LA Start S	Deceleration time, ms	216±46	210 (4.70)	220 (4.30)	222 (4.60)	0.07		
LAVs LA maximal volume, mL 61±20 60 (1.60) 59 (1.50) 61 (1.60) 0.61 LA maximal volume, mL 29±12 27 (1.00) 28 (0.91) 30 (0.99) 0.08 LA maximal volume indexed, mL/m ² 33±90 33 (0.90) 32 (0.87) 33 (0.88) 0.78 LA minimum volume indexed, mL/m ² 16±60 15 (0.50) 15 (0.54) 16 (0.59) 0.16 LA contractile function 15 (0.50) 15 (0.54) 16 (0.59) 0.48 LA stroke volume indexed, mL/m ² 18±60 18 (0.60) 17 (0.66) 17 (0.69) 0.48 LA exptore volume indexed, mL/m ² 18±60 18 (0.60) 10 (0.52 (0.01) 0.51 (0.01) 0.13 LA stroke volume indexed, mL/m ² 18±60 0.54 (0.01) 0.52 (0.01) 0.51 (0.01) 0.13 LA exptori function 53±11 54 (1.20) 52 (1.01) 52 (1.01) 0.51 (0.01) 0.14* LA exptori function 125±59 138 (6.10) 122 (5.60) 118 (6) 0.040* <td>3DE</td> <td></td> <td></td> <td></td> <td></td> <td></td>	3DE							
LA maximal volume, mL 61 ± 20 $60(1.60)$ $59(1.50)$ $61(1.60)$ 0.61 LA minimum volume, mL 29 ± 12 $27(1.00)$ $28(0.91)$ $30(0.99)$ 0.08 LA maximal volume indexed, mL/m2 33 ± 90 $33(0.90)$ $32(0.87)$ $33(0.88)$ 0.78 LA minimum volume indexed, mL/m2 16 ± 60 $15(0.50)$ $15(0.54)$ $16(0.59)$ 0.16 LA contractile function 16 ± 60 $15(0.50)$ $15(0.54)$ $16(0.59)$ 0.16 LA stroke volume indexed, mL/m2 18 ± 60 $18(0.60)$ $17(0.66)$ $17(0.69)$ 0.48 LA stroke volume indexed, mL/m2 18 ± 60 $18(0.60)$ $17(0.66)$ $17(0.69)$ 0.48 LA esprasion indexed, mL/m2 18 ± 60 $18(0.60)$ $17(0.69)$ 0.48 LA emptying fraction, % 0.5 ± 0.10 $0.54(0.01)$ $0.52(0.01)$ $0.51(0.01)$ 0.13 LA reservoir function 19 ± 60 $21(0.60)$ $19(0.66)$ $18(0.68)$ 0.014^* LA expansion index 12 ± 59 $138(6.10)$ $122(5.60)$ $118(6)$ 0.040^* LA conduit function 12 ± 12 $33(1.20)$ $31(1.10)$ $31(1.20)$ 0.47 LA conduit volume, mL 3 ± 80 $6(0.30)$ $11(0.34)$ $4(0.36)$ 0.64 LA stiffness $16(0.44)$ $0.52(0.04)$ $0.61(0.04)$ $0.72(0.04)$ 0.001^* E/e' divided by LA GLS 0.63 ± 0.50 $0.52(0.04)$ $0.61(0.04)$ $0.24(0.01)$ 0.01^*	LAVs							
LA minimum volume, mL 29±12 27 (1.00) 28 (0.91) 30 (0.99) 0.08 LA maximal volume indexed, mL/m2 33±90 33 (0.90) 32 (0.87) 33 (0.88) 0.78 LA minimum volume indexed, mL/m2 16±60 15 (0.50) 15 (0.54) 16 (0.59) 0.16 LA contractile function 18±60 18 (0.60) 17 (0.66) 17 (0.69) 0.48 LA EF, % 53±11 54 (1.20) 52 (1.01) 52 (1.10) 0.13 LA emptying fraction, % 0.5±0.10 0.54 (0.01) 0.52 (0.01) 0.51 (0.01) 0.13 LA reservoir function 19±60 21 (0.60) 19 (0.66) 18 (0.68) 0.014° LA expansion index 12±59 138 (6.10) 122 (5.60) 118 (6) 0.040° LA conduit function 12±59 138 (6.10) 122 (5.60) 118 (6) 0.040° LA conduit function 15±80 6 (0.30) 11 (0.34) 4 (0.36) 0.64 LA conduit volume, mL <td< td=""><td>LA maximal volume, mL</td><td>61±20</td><td>60 (1.60)</td><td>59 (1.50)</td><td>61 (1.60)</td><td>0.61</td></td<>	LA maximal volume, mL	61±20	60 (1.60)	59 (1.50)	61 (1.60)	0.61		
LA maximal volume indexed, mL/m ² 33±90 33 (0.90) 32 (0.87) 33 (0.88) 0.78 LA minimum volume indexed, mL/m ² 16±60 15 (0.50) 15 (0.54) 16 (0.59) 0.16 LA contractile function 18 (0.60) 17 (0.66) 17 (0.69) 0.48 LA stroke volume indexed, mL/m ² 18±60 18 (0.60) 17 (0.66) 17 (0.69) 0.48 LA EF, % 53±11 54 (1.20) 52 (1.01) 52 (1.01) 0.13 LA emptying fraction, % 0.5±0.10 0.54 (0.01) 0.52 (0.01) 0.51 (0.01) 0.13 LA reservoir function 19±60 21 (0.60) 19 (0.66) 18 (0.68) 0.014* LA expansion index 125±59 138 (6.10) 122 (5.60) 118 (6) 0.040* LA conduit function 32±12 33 (1.20) 31 (1.10) 31 (1.20) 0.47 LA conduit function 15±80 6 (0.30) 11 (0.34) 4 (0.36) 0.64 LA stiffness <t< td=""><td>LA minimum volume, mL</td><td>29±12</td><td>27 (1.00)</td><td>28 (0.91)</td><td>30 (0.99)</td><td>0.08</td></t<>	LA minimum volume, mL	29±12	27 (1.00)	28 (0.91)	30 (0.99)	0.08		
LA minimum volume indexed, mL/m ² 16±60 15 (0.50) 15 (0.54) 16 (0.59) 0.16 LA contractile function LA contractile function LA stroke volume indexed, mL/m ² 18±60 18 (0.60) 17 (0.66) 17 (0.69) 0.48 LA EF, % 53±11 54 (1.20) 52 (1.01) 52 (1.10) 0.13 LA emptying fraction, % 0.5±0.10 0.54 (0.01) 0.52 (0.01) 0.51 (0.01) 0.13 LA reservoir function LA expansion index 19±60 21 (0.60) 19 (0.66) 18 (0.68) 0.014* LA expansion index 125±59 138 (6.10) 122 (5.60) 118 (6) 0.040* LA conduit function 125±59 138 (6.10) 122 (5.60) 118 (6) 0.040* LA conduit function 32±12 33 (1.20) 31 (1.10) 31 (1.20) 0.47 LA conduit volume, mL 15±80 6 (0.30) 11 (0.34) 4 (0.36) 0.64 LA stiffness E/e' divided by LA GLS 0.63±0.50 0.52 (0.04) 0.61 (0.04) 0.72 (0.04) 0.001*	LA maximal volume indexed, mL/m ²	33±90	33 (0.90)	32 (0.87)	33 (0.88)	0.78		
LA contractile function I8 ±60 18 (0.60) 17 (0.66) 17 (0.69) 0.48 LA stroke volume indexed, mL/m² 18±60 18 (0.60) 17 (0.66) 17 (0.69) 0.48 LA EF, % 53±11 54 (1.20) 52 (1.01) 52 (1.10) 0.13 LA emptying fraction, % 0.5±0.10 0.54 (0.01) 0.52 (0.01) 0.51 (0.01) 0.13 LA reservoir function 19±60 21 (0.60) 19 (0.66) 18 (0.68) 0.014* LA expansion index 125±59 138 (6.10) 122 (5.60) 118 (6) 0.040* LA conduit function 125±59 138 (6.10) 122 (5.60) 118 (6) 0.040* LA conduit function 125±59 138 (6.10) 122 (5.60) 118 (6) 0.040* LA conduit function 32±12 33 (1.20) 31 (1.10) 31 (1.20) 0.47 LA conduit volume, mL 15±80 6 (0.30) 11 (0.34) 4 (0.36) 0.64 LA stiffness E/e' divided by LA GLS 0.63±0.50 0.52 (0.04) 0.61 (0.04) 0.72 (0.04)	LA minimum volume indexed, mL/m ²	16±60	15 (0.50)	15 (0.54)	16 (0.59)	0.16		
LA stroke volume indexed, mL/m ² 18±60 18 (0.60) 17 (0.66) 17 (0.69) 0.48 LA EF, % 53±11 54 (1.20) 52 (1.01) 52 (1.10) 0.13 LA emptying fraction, % 0.5±0.10 0.54 (0.01) 0.52 (0.01) 0.51 (0.01) 0.13 LA reservoir function 0.5±0.10 0.54 (0.01) 0.52 (0.01) 0.51 (0.01) 0.13 LA GLS, % 19±60 21 (0.60) 19 (0.66) 18 (0.68) 0.014* LA expansion index 125±59 138 (6.10) 122 (5.60) 118 (6) 0.040* LA conduit function 125±59 138 (6.10) 122 (5.60) 118 (6) 0.040* LA emptying volume, mL 32±12 33 (1.20) 31 (1.10) 31 (1.20) 0.47 LA conduit volume, mL 15±80 6 (0.30) 11 (0.34) 4 (0.36) 0.64 LA stiffness 0.63±0.50 0.52 (0.04) 0.61 (0.04) 0.72 (0.04) 0.001* E/e' divided by LA GLS 0.63±0.50 0.52 (0.04) 0.61 (0.01) 0.24 (0.01) <td< td=""><td>LA contractile function</td><td></td><td>1</td><td>1</td><td></td><td>J</td></td<>	LA contractile function		1	1		J		
LA EF, % 53±11 54 (1.20) 52 (1.01) 52 (1.10) 0.13 LA emptying fraction, % 0.5±0.10 0.54 (0.01) 0.52 (0.01) 0.51 (0.01) 0.13 LA reservoir function 1 </td <td>LA stroke volume indexed, mL/m²</td> <td>18±60</td> <td>18 (0.60)</td> <td>17 (0.66)</td> <td>17 (0.69)</td> <td>0.48</td>	LA stroke volume indexed, mL/m ²	18±60	18 (0.60)	17 (0.66)	17 (0.69)	0.48		
LA emptying fraction, % 0.5±0.10 0.54 (0.01) 0.52 (0.01) 0.51 (0.01) 0.13 LA reservoir function	LA EF, %	53±11	54 (1.20)	52 (1.01)	52 (1.10)	0.13		
LA reservoir function LA GLS, % 19±60 21 (0.60) 19 (0.66) 18 (0.68) 0.014* LA expansion index 125±59 138 (6.10) 122 (5.60) 118 (6) 0.040* LA conduit function 125±12 33 (1.20) 31 (1.10) 31 (1.20) 0.47 LA emptying volume, mL 32±12 33 (1.20) 11 (0.34) 4 (0.36) 0.64 LA conduit volume, mL 15±80 6 (0.30) 11 (0.34) 4 (0.36) 0.64 LA stiffness 0.52 (0.04) 0.61 (0.04) 0.72 (0.04) 0.001* E/e' divided by LA GLS 0.63±0.50 0.52 (0.04) 0.61 (0.04) 0.72 (0.04) 0.001*	LA emptying fraction, %	0.5±0.10	0.54 (0.01)	0.52 (0.01)	0.51 (0.01)	0.13		
LA GLS, % 19±60 21 (0.60) 19 (0.66) 18 (0.68) 0.014* LA expansion index 125±59 138 (6.10) 122 (5.60) 118 (6) 0.040* LA conduit function 33 (1.20) 31 (1.10) 31 (1.20) 0.47 LA conduit volume, mL 32±12 33 (1.20) 31 (1.10) 31 (1.20) 0.47 LA conduit volume, mL 15±80 6 (0.30) 11 (0.34) 4 (0.36) 0.64 LA stiffness 0.63±0.50 0.52 (0.04) 0.61 (0.04) 0.72 (0.04) 0.001* E/e' divided by LA GLS 0.63±0.20 0.19 (0.01) 0.21 (0.01) 0.24 (0.01) 0.018*	LA reservoir function							
LA expansion index 125±59 138 (6.10) 122 (5.60) 118 (6) 0.040* LA conduit function	LA GLS, %	19±60	21 (0.60)	19 (0.66)	18 (0.68)	0.014*		
LA conduit function 32±12 33 (1.20) 31 (1.10) 31 (1.20) 0.47 LA emptying volume, mL 15±80 6 (0.30) 11 (0.34) 4 (0.36) 0.64 LA stiffness 5±80 0.52 (0.04) 0.61 (0.04) 0.72 (0.04) 0.001* E/e' divided by LA GLS 0.63±0.50 0.52 (0.04) 0.61 (0.04) 0.72 (0.04) 0.001*	LA expansion index	125±59	138 (6.10)	122 (5.60)	118 (6)	0.040*		
LA emptying volume, mL 32±12 33 (1.20) 31 (1.10) 31 (1.20) 0.47 LA conduit volume, mL 15±80 6 (0.30) 11 (0.34) 4 (0.36) 0.64 LA stiffness E/e' divided by LA GLS 0.63±0.50 0.52 (0.04) 0.61 (0.04) 0.72 (0.04) 0.001* E/e' divided by LA EF 0.20±0.20 0.19 (0.01) 0.21 (0.01) 0.24 (0.01) 0.018*	LA conduit function							
LA conduit volume, mL 15±80 6 (0.30) 11 (0.34) 4 (0.36) 0.64 LA stiffness E/e' divided by LA GLS 0.63±0.50 0.52 (0.04) 0.61 (0.04) 0.72 (0.04) 0.001* E/e' divided by LA GLS 0.20±0.20 0.19 (0.01) 0.21 (0.01) 0.24 (0.01) 0.018*	LA emptying volume, mL	32±12	33 (1.20)	31 (1.10)	31 (1.20)	0.47		
LA stiffness 0.63±0.50 0.52 (0.04) 0.61 (0.04) 0.72 (0.04) 0.001* E/e' divided by LA GLS 0.20±0.20 0.19 (0.01) 0.21 (0.01) 0.24 (0.01) 0.018*	LA conduit volume, mL	15±80	6 (0.30)	11 (0.34)	4 (0.36)	0.64		
E/e' divided by LA GLS 0.63±0.50 0.52 (0.04) 0.61 (0.04) 0.72 (0.04) 0.001* E/e' divided by LA EF 0.20±0.20 0.19 (0.01) 0.21 (0.01) 0.24 (0.01) 0.018*	LA stiffness	1	1	1				
E/e' divided by LA EF 0.20±0.20 0.19 (0.01) 0.21 (0.01) 0.24 (0.01) 0.018*	E/e' divided by LA GLS	0.63±0.50	0.52 (0.04)	0.61 (0.04)	0.72 (0.04)	0.001*		
	E/e' divided by LA EF	0.20±0.20	0.19 (0.01)	0.21 (0.01)	0.24 (0.01)	0.018*		

Overall characteristics are described as mean (±SD); after-adjustments variables according to cerebral infarcts are presented as mean (SE). All *P* values are adjusted for sex, race, body surface area, body mass index, blood pressure, heart rate, previous myocardial infarction, hypertension, diabetes, renal function, NT-proBNP (N-terminal pro-B-type natriuretic peptide)—troponins levels, anticoagulants usage, and antiplatelet agents. Age tertile 1=68±2 years, age tertile 2=76±2 years, and age tertile 3=83±3 years. 2DE indicates 2-dimensional echocardiography; 3DE, 3-dimensional echocardiography; ARIC-NCS, Atherosclerosis Risk in Communities Neurocognitive Study; EF, ejection fraction; GLS, global longitudinal strain; LA, left atrial; LAV, left atrial volume; and LV, left ventricular.

*Denotes statistcally significant differences across groups for the selected variable.

of SCIs among ARIC participants in the presence HF and sinus rhythm, while Sugimoto and colleagues¹² showed that LA reservoir function and stiffness modified with age.

Cardiac senescence is a complex process and is partially driven by age-related comorbidities such as

long-standing hypertension, vascular stiffness, and HF.^{2,30} Remodeling of cardiac chambers caused by aging³¹ involves both LA electrical remodeling and enlargement, and this increase in LA dimension has been demonstrated to be a robust and well-established

Table 3. Adjusted Mean 2DE and 3DE Characteristics According to Tertiles of Age and Cerebral Infarcts Phenotypes: the ARIC-NCS, 2011 to 2013 According to Tertiles of Age and Cerebral Infarcts Phenotypes: the

	Total	Age tertile 1	Age tertile 2	Age tertile 3	P for trend
Subclinical cerebral infarct	N=58	n=20	n=19	n=19	
LV dimensions and function	1		1	1	
LV end-diastolic diameter, cm	4.35±0.52	4.28 (0.04)	4.32 (0.04)	4.31 (0.04)	0.55
LV end-systolic diameter, cm	2.59±0.50	2.46 (0.04)	2.46 (0.04)	2.40 (0.04)	0.28
LV end-diastolic volume indexed, mL/m ²	49±12	45 (0.84)	44 (0.84)	44 (0.85)	0.47
LV end-systolic volume indexed, mL/m ²	18±70	15 (0.40)	14 (0.40)	14 (0.40)	0.39
LV relative wall thickness	0.45±0.10	0.42 (0.01)	0.44 (0.01)	0.45 (0.01)	0.35
LV EF, %	67±50	67 (0.50)	68 (0.50)	68 (0.50)	0.36
E/e' ratio, average	11±40	9 (0.39)	11 (0.41)	12 (0.45)	0.001*
LAVs	·				
LA maximal volume indexed, mL/m ²	36±12	31 (0.92)	32 (0.95)	35 (0.96)	0.003*
LA minimum volume indexed, mL/m ²	17±10	14 (0.55)	16 (0.57)	17 (0.58)	0.001*
LA contractile function	·				
LA stroke volume indexed, mL/m ²	19±65	17 (0.61)	17 (0.64)	17 (0.67)	0.66
LA EF (%)	54±14	55 (10)	52 (20)	51 (30)	0.008*
LA emptying fraction, %	54±0.14	55 (0.01)	51 (0.01)	50 (0.01)	0.009*
LA reservoir function			·		
LA GLS, %	21±66	21 (0.60)	19 (0.62)	17 (0.63)	0.001*
LA expansion index	138±76	134 (5.50)	119 (5.44)	114 (5.56)	0.009*
LA conduit function					
LA emptying volume, mL	35±14	31 (1.00)	31 (1.12)	32 (1.50)	0.70
LA conduit volume, mL	15±80	6 (0.32)	11 (0.35)	4 (0.38)	0.64
LA stiffness	·		^ 		
E/e' divided by LA GLS	0.58±0.37	0.53 (0.04)	0.60 (0.04)	0.81 (0.04)	0.001*
E/e' divided by LA EF	0.22±0.16	0.18 (0.01)	0.22 (0.01)	0.26 (0.01)	0.001*
Stroke	n=34	n=12	n=11	n=11	
LV dimensions and function	·				
LV end-diastolic diameter, cm	4.54±0.58	4.57 (0.19)	4.46 (0.20)	4.58 (0.19)	0.96
LV end-systolic diameter, cm	2.58±0.54	2.62 (0.17)	2.72 (0.18)	2.39 (0.18)	0.35
LV end-diastolic volume indexed, mL/m ²	50±15	50 (51)	52 (53)	47 (58)	0.72
LV end-systolic volume indexed, mL/m ²	17±80	17 (2.60)	19 (2.70)	15 (2.60)	0.52
LV relative wall thickness	0.46±0.10	0.44 (0.09)	0.46 (0.01)	0.50 (0.01)	0.042*
LV EF, %	67±50	66 (1.74)	65 (1.75)	69 (1.77)	0.31
E/e' ratio, average	10±50	8 (1.52)	9 (1.65)	14 (1.57)	0.015*
LAVs					
LA maximal volume indexed, mL/m ²	35±90	34 (30)	34 (32)	38 (33)	0.32
LA minimum volume indexed, mL/m ²	16±60	14 (1.92)	16 (1.95)	18 (1.99)	0.19
LA contractile function					
LA stroke volume indexed, mL/m ²	19±60	20 (20)	17 (21)	20 (23)	0.72
LA EF (%)	54±12	57 (3.50)	51 (3.61)	54 (3.66)	0.54
LA emptying fraction, %	54±0.12	57 (0.03)	52 (0.04)	53 (0.03)	0.47
LA reservoir function					
LA global longitudinal strain, %	20±70	23 (0.52)	20 (1.50)	18 (20)	0.045*
LA expansion index	129±50	145 (15)	115 (15)	126 (15)	0.40
LA conduit function					
LA emptying volume, mL	37±13	37 (40)	34 (43)	39 (46)	0.76

Table 3. Continued

	Total	Age tertile 1	Age tertile 2	Age tertile 3	P for trend
LA conduit volume, mL	15±80	6 (0.25)	11 (0.35)	4 (0.37)	0.64
LA stiffness					
E/e' divided by LA GLS	0.68±0.68	0.41 (0.19)	0.48 (0.20)	1.18 (0.20)	0.011*
E/e' divided by LA EF	0.21±0.13	0.16 (0.04)	0.19 (0.04)	0.28 (0.04)	0.048*

Total characteristics are described as mean (±SD); after-adjustments variables according to cerebral infarcts are presented as mean (SE). All of the *P* values are adjusted for age, sex, race, body surface area, body mass index, heart rate, blood pressure, NT-proBNP (N-terminal pro-B-type natriuretic peptide)— troponins levels, previous myocardial infarction, hypertension, diabetes, renal function, anticoagulants usage, and antiplatelet agents. Subclinical cerebral infarcts: age tertile 1=68±1 years, age tertile 2=76±1 years, and age tertile 3=82±3 years. Stroke: age tertile 1=68±1 years, age tertile 2=76±2 years, and age tertile 3=83±2 years. 2DE indicates 2-dimensional echocardiography; 3DE, 3-dimensional echocardiography; ARIC-NCS, Atherosclerosis Risk in Communities Neurocognitive Study; EF, ejection fraction; GLS, global longitudinal strain; LA, left atrial; LAV, left atrial volume; and LV, left ventricular.

 $\ensuremath{\,^{\ast}\text{Denotes}}$ statistically significant differences across groups for the selected variable.

predictor of cardiovascular events.³² In addition, studies in both animals and humans have shown that LA size increases with LAV and LA pressure, with an associated initial gain in contractile shortening and elevated LA GLS values.⁴ However, with progressive deterioration of LA function and structure, atrial shortening and contractility begin to decline.⁴ In this way, independently from the presence of AF and reduced EF, the solely atrial senescence could probably be sufficient to LA clot formation, causing SCIs first and, subsequently, clinically apparent stroke.

The left atrium is an extremely sensitive cardiac chamber, capable of detecting early effects of increased LV volume, pressure overload, and diastolic dysfunction.² A strong linear relationship between LAV and longitudinal deformation echocardiographic indices have been demonstrated in a wide variety of diseases and settings.^{11,33} Speckle tracking imaging techniques may serve as a surrogate of LV diastolic dysfunction and can also be used to quantify atrial phasic function and stiffness.¹² In our analysis, E/e' divided by LA GLS and LA GLS—2 indices of both LA stiffness



Figure. Differences of left atrial (LA) global longitudinal strain (GLS) 3-dimensional echocardiography strain analysis according to age tertiles in the overall population and through the spectrum of cerebral infarcts phenotypes, from subclinical cerebral infarcts (SCIs) to stroke.

A, The overall population: age tertile $1=68\pm2$ years, age tertile $2=76\pm2$ years, and age tertile $3=83\pm3$ years. **B**, SCIs: age tertile $1=68\pm1$ years, age tertile $2=76\pm1$ years, and age tertile $3=82\pm3$ years. **C**, Stroke: age tertile $1=68\pm1$ years, age tertile $2=76\pm2$ years, and age tertile 3=83.

		Subclinical cerebral infarcts		Stroke					
Age tertiles	Predictors	OR	95% CI	P value	Interaction P value	OR	95% CI	P value	Interaction <i>P</i> value
First tertile	CHA2DS2-VASc score, per 1 point	1.42	1.24–5.27	0.003*	0.58	1.53	1.26-3.63	0.017*	0.45
Second tertile		1.55	1.32-5.07	0.018*		1.62	1.16-2.25	0.005*	
Third tertile		2.02	2.72-5.66	0.0001*		3.50	3.36-4.75	0.001*	
First tertile	NT-proBNP, per 1 ng/L	1.62	1.16–2.25	0.005*	0.65	1.26	1.03–5.33	0.028*	0.66
Second tertile		1.65	1.18–2.27	0.007*		2.96	2.03-4.33	0.002*	
Third tertile		2.71	1.51-4.87	0.001*		2.45	2.23-3.23	0.0001*	
First tertile	High-sensitivity troponin T, per 1 ng/mL	1.67	0.61-4.32	0.33	0.34	2.71	1.51–5.87	0.016*	0.27
Second tertile		1.76	0.72-5.68	0.78		3.02	1.71–4.89	0.005*	
Third tertile		2.53	0.85–7.63	0.99		3.76	2.05-4.73	0.001*	
First tertile	LA EF, per 1%	0.35	0.25-0.98	0.004*	0.27	0.43	0.15-1.24	0.11	0.16
Second tertile		0.77	0.47-0.88	0.001*		0.65	0.24–1.28	0.55	
Third tertile		0.95	0.92-0.99	0.0001*		0.98	0.05–1.39	0.71	
First tertile	LA GLS, per 1%	0.32	0.30-0.97	0.036*	0.043*	0.21	0.19–0.99	0.043*	0.040*
Second tertile		0.58	0.52-0.69	0.008*		0.50	0.36-0.66	0.015*	
Third tertile		0.75	0.70-0.78	0.001*		0.56	0.53-0.60	0.001*	
First tertile	E/e' divided by LA GLS, per unit	1.53	1.42–1.67	0.037*	0.010*	1.02	1.01–1.22	0.045*	0.08
Second tertile		1.75	1.68–1.79	0.007*		1.25	1.22-2.34	0.007*	
Third tertile		2.53	2.50-2.57	0.001*		1.38	1.25–1.63	0.003*	

Table 4. Correlates of SCIs and Stroke and Their Interactions for Age Tertiles in Participants With Sinus Rhythm, Normal EF, and No History of AF: ARIC-NCS, 2011 to 2013

Stratified multivariable logistic regression over age tertiles and interactions between age tertiles and predictors for subclinical cerebral infarcts (SCIs) and stroke. AF indicates atrial fibrillation; ARIC-NCS, Atherosclerosis Risk in Communities Neurocognitive Study; EF, ejection fraction; GLS, global longitudinal strain; LA, left atrial; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and OR, odds ratio.

*Denotes statistcally significant OR.

and LA reservoir function—were the LA function parameters found to be associated with increased odds of overall cerebral events (SCIs and clinical stroke), and these indexes showed a significant interaction with age for SCIs.

Therefore, 3DE LA indexes of reservoir impairment and stiffness appear to be altered early because of aging, even before any other change in traditional LA echocardiographic volume-related parameter.³¹ Consequently, LA GLS analysis may be a much more sensitive tool in detecting subclinical atrial dysfunction before the occurrence of changes in traditional echocardiographic parameters.

Limitations

The relatively small study sample and the crosssectional design of this study are the principal limitations of our investigation. In addition, it may have been underpowered to detect differences in other echocardiographic parameters, especially those related to the LV structure and both systolic and diastolic function. Moreover, we cannot exclude the presence of subclinical AF since we do not have data regarding continuous ECG monitoring, but from visit 3 to 5, our participants did not experience hospitalizations attributable to AF and were always found in sinus rhythm at the examinations. Next, 336 3DE images were excluded from our analysis because of insufficient 3DE image quality. However, these missing data were likely random in nature and should not have biased our results. Finally, although we adjusted our analysis for potential confounders, we cannot exclude residual confounding.

CONCLUSIONS

In a large cohort study of elderly patients, among participants with normal EF, sinus rhythm, and no history of AF, measures of worsening age-related LA reservoir function and stiffness are associated with higher odds of SCIs and stroke.

ARTICLE INFORMATION

Received October 9, 2021; accepted March 1, 2022.

Affiliations

Department of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (F.B., A.C., I.A., B.C., A.G., A.S., S.D.S.); Cardio-Thoracic and

Vascular Department, Pisa University Hospital, University of Pisa, Pisa, Italy (R.D.C.); Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD (M.C.J., R.G.); Center for Cardiac Arrest Prevention, Department of Cardiology, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA (F.L.N.); Lillehei Heart Institute and Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, MN (R.C., L.Y.C.); Wake Forest University, Winston-Salem, NC (E.Z.S.); Department of Medicine, University of Medical Center, Jackson, MS (T.M.); Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA (A.A.); and University of Porto Medical School, Porto, Portugal (A.G.).

Acknowledgments

The authors thank the staff and participants of the ARIC study and Pio Caso, MD, Scipione Carrerj, MD, and Alessandro Capucci, MD, for their important contributions.

Sources of Funding

The ARIC study is performed as a collaborative investigation supported by National Heart, Lung, and Blood Institute contracts HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C. Neurocognitive data are collected by U01 HL096812, HL096814, HL096899, HL096902, and HL096917 with previous brain MRI examinations funded by R01-HL70825. Dr Chen is supported by R01 HL126637, R01 HL141288, RF1 NS127266, R01 HL158022, and K24 HL155813.

Disclosures

The authors declare no conflicts of interest as to the content of this article.

Supplemental Material

Tables S1–S2 Figures S1–S2

REFERENCES

- Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, American Heart Association Statistics Committee and Stroke Statistics Subcommittee, et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. *Circulation*. 2017;135:e146–e603. doi: 10.1161/CIR.00000000000485
- Goncalves A, Hung CL, Claggett B, Nochioka K, Cheng S, Kitzman DW, Shah AM, Solomon SD. Left atrial structure and function across the spectrum of cardiovascular risk in the elderly: the Atherosclerosis Risk in Communities Study. *Circ Cardiovasc Imaging*. 2016;9:e004010. doi: 10.1161/CIRCIMAGING.115.004010
- Thomas L, Abhayaratna WP. Left atrial reverse remodeling: mechanisms, evaluation, and clinical significance. JACC Cardiovasc Imaging. 2017;10:65–77. doi: 10.1016/j.jcmg.2016.11.003
- Blume GG, McLeod CJ, Barnes ME, Seward JB, Pellikka PA, Bastiansen PM, Tsang TS. Left atrial function: physiology, assessment, and clinical implications. *Eur J Echocardiogr.* 2011;12:421–430. doi: 10.1093/ejech ocard/jeq175
- Hassell ME, Nijveldt R, Roos YB, Majoie CB, Hamon M, Piek JJ, Delewi R. Silent cerebral infarcts associated with cardiac disease and procedures. *Nat Rev Cardiol*. 2013;10:696–706. doi: 10.1038/nrcardio.2013.162
- Hu X, De Silva TM, Chen J, Faraci FM. Cerebral vascular disease and neurovascular injury in ischemic stroke. *Circ Res.* 2017;120:449–471. doi: 10.1161/CIRCRESAHA.116.308427
- Bogousslavsky J, Cachin C, Regli F, Despland PA, Van Melle G, Kappenberger L. Cardiac sources of embolism and cerebral infarction– clinical consequences and vascular concomitants: the Lausanne Stroke Registry. *Neurology*. 1991;41:855–859. doi: 10.1212/WNL.41.6.855
- Cogswell RJ, Norby FL, Gottesman RF, Chen LY, Solomon S, Shah A, Alonso A. High prevalence of subclinical cerebral infarction in patients with heart failure with preserved ejection fraction. *Eur J Heart Fail*. 2017;19:1303–1309. doi: 10.1002/ejhf.812
- Nochioka K, Quarta CC, Claggett B, Roca GQ, Rapezzi C, Falk RH, Solomon SD. Left atrial structure and function in cardiac amyloidosis. *Eur Heart J Cardiovasc Imaging*. 2017;18:1128–1137. doi: 10.1093/ehjci/ jex097

- Voigt JU, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R, Pedri S, Ito Y, Abe Y, Metz S, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. *J Am Soc Echocardiogr.* 2015;28:183–193. doi: 10.1016/j. echo.2014.11.003
- Vieira MJ, Teixeira R, Goncalves L, Gersh BJ. Left atrial mechanics: echocardiographic assessment and clinical implications. J Am Soc Echocardiogr. 2014;27:463–478. doi: 10.1016/j.echo.2014.01.021
- Sugimoto T, Robinet S, Dulgheru R, Bernard A, Ilardi F, Contu L, Addetia K, Caballero L, Kacharava G, Athanassopoulos GD, et al. Echocardiographic reference ranges for normal left atrial function parameters: results from the EACVI NORRE study. *Eur Heart J Cardiovasc Imaging*. 2018;19:630–638. doi: 10.1093/ehjci/jey018
- The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989;129:687–702.
- Knopman DS, Griswold ME, Lirette ST, Gottesman RF, Kantarci K, Sharrett AR, Jack CR, Graff-Radford J, Schneider AL, Windham BG, et al. Vascular imaging abnormalities and cognition: mediation by cortical volume in nondemented individuals: Atherosclerosis Risk in Communities-Neurocognitive Study. *Stroke*. 2015;46:433–440. doi: 10.1161/STROKEAHA.114.007847
- Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ, Folsom AR. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. *Am Heart J.* 2009;158:111–117. doi: 10.1016/j.ahj.2009.05.010
- Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol.* 2013;12:822–838. doi: 10.1016/S1474-4422(13)70124-8
- Kantarci K, Weigand SD, Przybelski SA, Shiung MM, Whitwell JL, Negash S, Knopman DS, Boeve BF, O'Brien PC, Petersen RC, et al. Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS. *Neurology*. 2009;72:1519–1525. doi: 10.1212/WNL.0b013e3181a2e864
- Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, Copper LS, Shahar E. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. *Stroke*. 1999;30:736–743. doi: 10.1161/01. STR.30.4.736
- Shah AM, Cheng S, Skali H, Wu J, Mangion JR, Kitzman D, Matsushita K, Konety S, Butler KR, Fox ER, et al. Rationale and design of a multicenter echocardiographic study to assess the relationship between cardiac structure and function and heart failure risk in a biracial cohort of community-dwelling elderly persons: the Atherosclerosis Risk in Communities study. *Circ Cardiovasc Imaging*. 2014;7:173–181. doi: 10.1161/CIRCIMAGING.113.000736
- Hung CL, Goncalves A, Shah AM, Cheng S, Kitzman D, Solomon SD. Age- and sex-related influences on left ventricular mechanics in elderly individuals free of prevalent heart failure: the ARIC Study (Atherosclerosis Risk in Communities). *Circ Cardiovasc Imaging*. 2017;10:e004510. doi: 10.1161/CIRCIMAGING.116.004510
- Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr.* 2015;28:1–39.e14. doi: 10.1016/j. echo.2014.10.003
- Alonso A, Knopman DS, Gottesman RF, Soliman EZ, Shah AJ, O'Neal WT, Norby FL, Mosley TH, Chen LY. Correlates of dementia and mild cognitive impairment in patients with atrial fibrillation: the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). *J Am Heart Assoc.* 2017;6:e006014. doi: 10.1161/JAHA.117.006014
- Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). *Am J Cardiol.* 2008;101:1016–1022. doi: 10.1016/j. amjcard.2007.11.061
- 24. Sharrett AR, Patsch W, Sorlie PD, Heiss G, Bond MG, Davis CE. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. *Arterioscler Thromb.* 1994;14:1098–1104. doi: 10.1161/01.ATV.14.7.1098

- Maheshwari A, Norby FL, Soliman EZ, Koene RJ, Rooney MR, O'Neal WT, Alonso A, Chen LY. Abnormal P-wave axis and ischemic stroke: the ARIC Study (Atherosclerosis Risk In Communities). *Stroke*. 2017;48:2060–2065. doi: 10.1161/STROKEAHA.117.017226
- McEvoy JW, Chen Y, Ndumele CE, Solomon SD, Nambi V, Ballantyne CM, Blumenthal RS, Coresh J, Selvin E. Six-year change in highsensitivity cardiac troponin T and risk of subsequent coronary heart disease, heart failure, and death. *JAMA Cardiol.* 2016;1:519–528. doi: 10.1001/jamacardio.2016.0765
- Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20–29. doi: 10.1056/NEJMoa1114248
- Yaghi S, Kamel H. Stratifying stroke risk in atrial fibrillation: beyond clinical risk scores. *Stroke*. 2017;48:2665–2670. doi: 10.1161/STROK EAHA.117.017084
- Holmqvist F, Platonov PG, McNitt S, Polonsky S, Carlson J, Zareba W, Moss AJ; Investigators MI. Abnormal P-wave morphology is a predictor of atrial fibrillation development and cardiac death in MADIT

II patients. Ann Noninvasive Electrocardiol. 2010;15:63–72. doi: 10.1111/j.1542-474X.2009.00341.x

- Chiarelli AM, Bianco F, Perpetuini D, Bucciarelli V, Filippini C, Cardone D, Zappasodi F, Gallina S, Merla A. Data-driven assessment of cardiovascular ageing through multisite photoplethysmography and electrocardiography. *Med Eng Phys.* 2019;73:39–50. doi: 10.1016/j.meden gphy.2019.07.009
- Boyd AC, Richards DA, Marwick T, Thomas L. Atrial strain rate is a sensitive measure of alterations in atrial phasic function in healthy ageing. *Heart*. 2011;97:1513–1519. doi: 10.1136/heartjnl-2011-300134
- Gupta S, Matulevicius SA, Ayers CR, Berry JD, Patel PC, Markham DW, Levine BD, Chin KM, de Lemos JA, Peshock RM, et al. Left atrial structure and function and clinical outcomes in the general population. *Eur Heart J.* 2013;34:278–285. doi: 10.1093/eurhearti/ehs188
- Tsujiuchi M, Yamauchi T, Ebato M, Maezawa H, Nogi A, Ikeda N, Mizukami T, Nagumo S, Iso Y, Nakadate T, et al. Prognostic value of left atrial size and functional indices measured by 3-dimensional speckle-tracking analysis. *Circ J*. 2019;83:801–808. doi: 10.1253/circj. CJ-18-0554

SUPPLEMENTAL MATERIAL

	Total	Age tertile 1	Age tertile 2	Age tertile 3	
General characteristics	N=336	N=112	N=112	N=112	
Age (yr.)	76 ± 5	67 ± 3	75 ± 2	82 ± 3	
SCIs, n (%)	55 (16 %)	13 (11 %)	16 (14 %)	26 (23 %)	
Stroke, n (%)	35 (10 %)	15 (14 %)	6 (5 %)	14 (12 %)	
White, n (%)	322 (95 %)	100 (89 %)	110 (98 %)	111 (99 %)	
Male sex, n (%)	167 (50 %)	56 (50 %)	57 (51 %)	54 (48 %)	
Heart rate (bpm)	61 ± 10	63 ± 9	60 ± 11	59 ± 10	
Systolic blood pressure (mmHg)	133 ± 19	128 ± 18	136 ± 18	137 ± 18	
Diastolic blood pressure (mmHg)	67 ± 10	68 ± 10	67 ± 10	65 ± 10	
CHA ₂ DS ₂ -VASc score	4 (3, 4)	2 (2, 3)	3 (3, 4)	4 (4, 5)	
Height (cm)	167 ± 10	167 ± 9	165 ± 10	163 ± 8	
Weight (kg)	78 ± 15	77 ± 15	74 ± 15	72 ± 14	
BMI (kg/m ²)	28 ± 5	28 ± 4	27 ± 5	26 ± 5	
Previous myocardial infarction, n (%)	24 (7 %)	6 (5 %)	8 (7 %)	10 (9 %)	
HFpEF, n (%)	29 (9 %)	8 (7 %)	9 (8 %)	12 (11 %)	
Diabetes, n (%)	150 (45 %)	52 (46 %)	51 (45 %)	47 (42 %)	
Hypertension, n (%)	321 (95 %)	100 (89 %)	110 (98 %)	111 (99 %)	
Current and former smoking, n (%)	260 (77 %)	85 (76 %)	94 (84 %)	81 (72 %)	
Chronic kidney disease, n (%)	23 (7 %)	6 (5 %)	7 (6 %)	10 (9 %)	
Blood samples					
eGFR	76 ± 19	81 ± 17	73 ± 20	70 ± 20	
Total Cholesterol (mg/dL)	180 ± 41	184 ± 42	182 ± 43	175 ± 38	
LDL (mg/dL)	103 ± 33	106 ± 34	106 ± 33	98 ± 32	
HDL (mg/dL)	52 ± 14	53 ± 14	52 ± 15	52 ± 12	
Triglycerides (mg/dL)	124 ± 58	129 ± 64	122 ± 55	123 ± 54	
Glucose (mg/dL)	113 ± 33	116.3 ± 41.2	112.9 ± 30.4	111 ± 26	
Creatinine (mg/dL)	1.15 ± 0.4	0.9 ± 0.2	1.02 ± 0.6	1.10 ± 0.4	
Hs-C-Reactive Protein (mg/dL)	1.5 (0.6, 3.3)	1.7 (0.6, 3.2)	1.6 (0.8, 3.7)	1.8 (0.9, 3.7)	
Hs-Troponin T (ng/mL)	1.02 (0.7, 1.5)	0.8 (0.5, 1.2)	1 (0.7, 1.5)	1.2 (0.7, 1.7)	
NT-proBNP (ng/L)	132 (72, 235)	78 (46, 132)	133 (69, 240)	191 (121, 345)	
Medications				0.0)	
Statins, n (%)	190 (56 %)	65 (58 %)	62 (55 %)	63 (56 %)	
Anticoagulants, n (%)	10 (3 %)	5 (4 %)	3 (2 %)	2 (1 %)	
Aspirin, n (%)	280 (83 %)	88 (78 %)	90 (80 %)	102 (91 %)	
Beta-blockers, n (%)	112 (33 %)	42 (37 %)	32 (28 %)	37 (33 %)	
Anti-angiotensin II, n (%)	45 (12 %)	10 (9 %)	12 (10 %)	23 (20 %)	
ACE-I, n (%)	70 (22 %)	17 (15 %)	30 (27 %)	23 (20 %)	
Loop diuretics, n (%)	40 (12 %)	17 (15 %)	14 (12 %)	9 (8 %)	

Table S1. Clinical Characteristics of Excluded Participants due to insufficient 3DE image-quality according to age tertiles, the ARIC NCS, 2011-13

Legend: Data are described as mean (±SD) or median (Q1, Q3) for quantitative variables, and counts (proportions) for categorical variables. Three-dimensional echocardiography (3DE), years (yr.), milliseconds (ms), millimeters (mm), milliliters (mL), deciliters (dL), meters (m), centimeters (cm), numbers (n), estimated glomerular filtration rate (eGFR), left ventricle (LV), standard deviation (SD), subclinical cerebral infarcts (SCIs), heart failure with preserved ejection fraction (HFpEF).

Table S2. Adjusted mean 2D/3D Echocardiographic characteristics according to tertiles of age and cerebral infarcts phenotypes, the ARIC NCS, 2011-13

	Total	Age tertile 1	Age tertile 2	Age tertile 3	
No Cerebral Infarcts (NCIs)	N=315	N=105	N=105	N=105	P for Trend
LV dimensions and function					
LV end-diastolic diameter (cm)	4.30 ± 0.48	4.46 (0.10)	4.27 (0.10)	4.33 (0.11)	0.39
LV end-systolic diameter (cm)	2.44 ± 0.40	2.54 (0.10)	2.62 (0.10)	2.61 (0.10)	0.62
LV end-diastolic volume indexed (mL/m^2)	44 ± 9.5	49 (2.54)	51 (2.55)	46 (2.62)	0.50
LV end-systolic volume indexed (mL/m ²)	$\begin{array}{c} 14.38 \pm \\ 4.45 \end{array}$	17 (1.45)	19 (1.45)	16 (1.49)	0.91
LV relative wall thickness	0.44 ± 0.12	0.42 (0.01)	0.5 (0.01)	0.45 (0.02)	0.71
E/e' ratio, average	11 ± 4	9.5 (0.9)	11 (0.9)	12 (0.9)	0.40
Left atrial volumes					
LA maximal volume indexed (mL/m ²)	33 ± 9	31.9 (2.6)	40.3 (2.6)	36 (2.7)	0.26
LA minimum volume indexed (mL/m ²)	16 ± 6	13.7 (2.2)	20.8 (2.2)	16 (2.3)	0.46
LA contractile function					
LA stroke volume indexed (mL/m^2)	17 ± 6	18 (1.4)	19 (1.4)	20 (1.5)	0.31
LA ejection fraction (%)	52 ± 11	57 (3)	51 (3.1)	54 (3.2)	0.42
LA emptying fraction (%)	52 ± 0.12	58 (0.03)	51 (0.03)	54 (0.03)	0.38
Left atrial reservoir function					
LA global longitudinal strain (%)	19 ± 6	23 (1.4)	18 (1.4)	22 (1.4)	0.42
LA expansion index	122 ± 56	159 (17)	119 (18)	135 (18)	0.34
Left atrial conduit function					
LA emptying volume (mL)	31 ± 12	34 (2.5)	35 (2.5)	37 (2.6)	0.37
LA conduit volume (mL)	15 ± 8	6 (0.3)	11 (0.3)	4 (0.3)	0.64
Left atrial stiffness					
E/e' divided by LA GLS	0.64 ± 0.42	0.45 (0.08)	0.76 (0.08)	0.54 (0.08)	0.43

Legend: total characteristics are described as mean (\pm SD); after-adjustments variables according to cerebral infarcts are presented as mean (SE). Left atrium (LA), global longitudinal strain (GLS), milliseconds (ms), millimeters (mm), milliliters (mL), deciliters (dL), meters (m), centimeters (cm). All the P-values are adjusted for sex, race, body surface area (BSA), body mass index (BMI), heart rate, blood pressure, NT-proBNP - Troponins levels, previous myocardial infarction, hypertension, diabetes, renal function, anticoagulants usage and antiplatelet agents. Age tertile $1 = 68 \pm 2$ yr., age tertile $2 = 76 \pm 2$ yr., Age tertile $3 = 83 \pm 3$ yr.

0.49

Figure S1. Patient selection for the current study.



Abbreviations: Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS), magnetic resonance imaging (MRI), 3-dimensional (3D), atrial fibrillation (AF), ejection fraction (EF), left ventricle (LV). Figure S2. Frequency distribution of SCIs and stroke according to age-tertiles.



Abbreviations: SCIs: Subclinical cerebral infarcts. Age-tertile $1 = 70 \pm 2$ yr., Age-tertile $2 = 76 \pm 2$ yr., Age-tertile $3 = 83 \pm 3$ yr.